A Study of Doripenem in Infants Less Than 12 Weeks of Age
2013年1月8日 更新者:Janssen Research & Development, LLC
An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age
The purpose of this study is to measure drug levels of doripenem in blood samples collected before and after administration of doripenem to infants less than 12 weeks of age who are hospitalized and documented, presumed to have, or are at risk for bacterial infection (s) and are undergoing treatment with intravenous (i.v.) antibiotics.
Safety and tolerability will also be assessed.
研究概览
详细说明
This is a multicenter, open-label (identity of treatment is known to patient's parent/legal guardian/caregiver and to all study staff) pharmacokinetic study (a study to observe how the drug is absorbed and distributed within the body) to measure drug levels of doripenem in hospitalized but medically stable infants (term and preterm), <12 weeks of chronological age (CA) (age since time of birth) who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with intravenous (i.v.) (administered in a vein) antibiotics.
Doripenem will be administered alone at any time after the first dose of a nonstudy antibiotic is administered to the patient.
Doripenem is not being used in this study to treat infection and it will not replace the patient's prescribed antibiotic(s).
The duration of the study will be up to 9 days for each patient.
Patients' safety will be monitored throughout the study by a safety committee who will review safety information at least once a month or after every 8 patients are enrolled and dosed.
Safety evaluation will include, but will not be limited to, adverse events, clinical laboratory tests, and vital signs.
A single dose of study drug (doripenem) will be administered to patients in a hospitalized setting.
Patients <8 weeks CA will receive a 5 mg/kg doripenem 1-hour i.v.
infusion, and patients >=8 weeks CA will receive an 8 mg/kg doripenem 1-hour infusion.
Study drug will be administerd to the patient alone at any time after the first dose of a nonstudy antibiotic is administered to the patient.
研究类型
介入性
注册 (实际的)
52
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
不超过 2个月 (孩子)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Must be hospitalized, medically stable, without acute decline in physical condition in the inestigator's judgement
- Documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. antibiotics
- Patient's weight (kg) must be within the 5th and the 95th percentile inclusive for his or her age
- Parent or the patient's legally acceptable representative must have signed an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to allow the infant to participate in the study
Exclusion Criteria:
- Clinically significant abnormal values for hematology or clinical chemistry at screening as deemed appropriate by the investigator
- Clinically significant abnormal physical examination or vital signs at screening, as deemed appropriate by the investigator
- Patients who, in the investigator's judgment, have compromised renal (kidney) function including renal failure
- History of clinically significant allergies to medications, especially known hypersensitivity or intolerance to carbapenems, penicillins, or other beta lactam antibiotics
- Known allergy to heparin or history of heparin-induced thrombocytopenia, if an indwelling cannula (e.g., heparin lock) or central line is used
- Patients concomitantly treated with or having received imipenem/cilastin within 48 hours before study drug administration
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:001
Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
|
Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Doripenem concentrations in blood samples
大体时间:Before and after study drug administration for 1 day
|
Before and after study drug administration for 1 day
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Number of patients with adverse events
大体时间:Up to Day 7
|
Up to Day 7
|
|
Changes in clinical laboratory test results
大体时间:From Day -2 to Day 1
|
From Day -2 to Day 1
|
|
Changes in vital signs measurements
大体时间:From Day -2 to Day 1
|
From Day -2 to Day 1
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2009年10月1日
初级完成 (实际的)
2012年4月1日
研究完成 (实际的)
2012年4月1日
研究注册日期
首次提交
2011年4月21日
首先提交符合 QC 标准的
2011年6月24日
首次发布 (估计)
2011年6月27日
研究记录更新
最后更新发布 (估计)
2013年1月10日
上次提交的符合 QC 标准的更新
2013年1月8日
最后验证
2013年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.